Literature DB >> 34524009

Telemetric Continuous Glucose Monitoring During the COVID-19 Pandemic in Isolated Hospitalized Patients in Denmark: A Randomized Controlled Exploratory Trial.

Carina Kirstine Klarskov1, Nicole Avlund Windum1, Mikkel Thor Olsen1, Arnold Matovu Dungu2, Andreas Kryger Jensen3,4, Birgitte Lindegaard2,5, Ulrik Pedersen-Bjergaard1,5, Peter Lommer Kristensen1,5.   

Abstract

Objective: To investigate whether telemetric continuous glucose monitoring (CGM) in hospitalized and isolated patients with diabetes mellitus and coronavirus disease 2019 (COVID-19) is associated with better glycemic outcomes and fewer patient health care worker contacts compared to blood glucose monitoring by traditional point-of-care (POC) glucose testing and to investigate the user aspect of implementing a CGM-system in-hospital. Materials and
Methods: A randomized controlled exploratory trial was performed on hospitalized and isolated patients with diabetes and COVID-19 from May 2020 until February 2021 at Nordsjællands Hospital, Denmark. Participants were randomized to nonblinded telemetric CGM (as the only glucose monitoring method) or traditional POC glucose testing + blinded CGM. The primary endpoint was time in range (TIR) based on CGM data in both groups. A questionnaire about the user aspect of the CGM system was answered by health care personnel (HCP).
Results: We included 64 participants in the analysis, 31 in the CGM group and 33 in the POC glucose group. TIR median was 46% for the CGM group and 68% for the POC glucose group (P = 0.368). The mean glucose value for the CGM group was 11.1 and 10.8 mmol/L in the POC glucose group (P = 0.372). CGM was associated with fewer POC glucose measurements (P < 0.001). Out of 30 HCPs, 28 preferred telemetric CGM over POC glucose testing.
Conclusion: Remote glucose monitoring by CGM did not improve glycemic outcomes compared to traditional POC glucose testing, but was associated with fewer patient-personnel contacts, saving time for HCPs performing diabetes-related tasks. Most HCPs preferred CGM. The study is registered at http://www.clinicaltrials.gov (#NCT04430608).

Entities:  

Keywords:  COVID-19; Continuous glucose monitoring; Diabetes mellitus; Infection; Isolation; Personal protective equipment; Telemetric medicine

Mesh:

Substances:

Year:  2022        PMID: 34524009     DOI: 10.1089/dia.2021.0291

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  3 in total

1.  Glycemic variability assessed by continuous glucose monitoring in hospitalized patients with community-acquired pneumonia.

Authors:  Mikkel Thor Olsen; Arnold Matovu Dungu; Carina Kirstine Klarskov; Andreas Kryger Jensen; Birgitte Lindegaard; Peter Lommer Kristensen
Journal:  BMC Pulm Med       Date:  2022-03-09       Impact factor: 3.317

Review 2.  COVID-19 and Diabetes Outcomes: Rationale for and Updates from the CORONADO Study.

Authors:  Sarra Smati; Blandine Tramunt; Matthieu Wargny; Pierre Gourdy; Samy Hadjadj; Bertrand Cariou
Journal:  Curr Diab Rep       Date:  2022-02       Impact factor: 5.430

Review 3.  Impacts on Context Aware Systems in Evidence-Based Health Informatics: A Review.

Authors:  Stella C Christopoulou
Journal:  Healthcare (Basel)       Date:  2022-04-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.